ReviewCurrent treatment options in cardiovascular medicine2018
Immune Modulation in Heart Failure: the Promise of Novel Biologics.
Review in Current treatment options in cardiovascular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects.Clinical drug investigation · 2020Trial
- Prognostic nutritional index and geriatric nutritional risk index as predictors of in-hospital major adverse cardiovascular events after percutaneous coronary intervention in acute coronary syndrome patients: a multicenter retrospective cohort study.Frontiers in nutrition · 2026Article
- Exploring the effects and mechanisms of Guizhigancao Decoction on heart failure using an integrated approach based on experimental support and network pharmacology strategy.Journal of traditional and complementary medicine · 2023Article
- Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy.Heart failure reviews · 2023Review
- Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure.European journal of heart failure · 2022Article
- New factors in heart failure pathophysiology: Immunity cells release of extracellular vesicles.Frontiers in cardiovascular medicine · 2022Article
- The relationship of α-hydroxybutyrate dehydrogenase with 1-year outcomes in patients with intracerebral hemorrhage: A retrospective study.Frontiers in neurology · 2022Article
- Crossroads between Estrogen Loss, Obesity, and Heart Failure with Preserved Ejection Fraction.Arquivos brasileiros de cardiologia · 2021Review
- The role of B cells in heart failure and implications for future immunomodulatory treatment strategies.ESC heart failure · 2020Review
- Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity.Frontiers in cardiovascular medicine · 2020Review
- Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling-Additional Information About TLR9 Involvement.Cardiovascular drugs and therapy · 2019Article
- Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales.Frontiers in cardiovascular medicine · 2019Review
- The interstitium in cardiac repair: role of the immune-stromal cell interplay.Nature reviews. Cardiology · 2018Review
- Intracerebral Hemorrhage Induces Cardiac Dysfunction in Mice Without Primary Cardiac Disease.Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewImmune system activation plays a central role in heart failure progression. Large-scale immune modulatory clinical trials targeting tumor necrosis factor-α and broad spectrum immune modulation have been negative. The objective of this review is to highlight past, present, and what is in the horizon for the immunomodulation in heart failure with a focus of biologics. RECENT
findingsStrategies targeting interleukin-1 pathway are currently undergoing clinical evaluation and data from pilot studies are promising. The potential of cell therapy for immune modulation is increasingly recognized in clinical trials. Strategies targeting anti-cardiac antibodies such as immunoadsorption and intravenous immunoglobulin have been used in clinical practice with positive outcomes but large pragmatic clinical trials are lacking. The use of an aptamer to block anti-cardiac antibodies is undergoing phase 1 clinical evaluation. Promising targets include inflammasomes, toll-like receptors, chemokines, natural killer cells, and macrophages. Large-scale immune modulatory clinical trials have been negative. Nevertheless, the experience gained from them along with increasing understanding of molecular mechanisms of immune pathophysiology in heart failure is leading to rapid recognition of new therapeutic targets and approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.